AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1287983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftereffect produced by adapting to rectangles of (a/b)ADAPT equal to 1.5, 1.0 and (1/1.5)
Number of subjects: 0
Study 3837132 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostin 15-M (8.92 ml, 28h 30' for group A; 8.23 ml, 23h 23' for group B; 4.97 ml, 16h for group C)
Number of subjects: 470
Study 31740859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan sustained natural apophyseal glides mobilization
Number of subjects: 40
Study 31740859 — intervention group
Group type: COMPARATOR
Intervention: Mulligan sustained natural apophyseal glides mobilization with thoracic postural correction techniques
Number of subjects: 40
Study 28462869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) given for 5 months in blended form (face-to-face and web-based sessions)
Number of subjects: 120
Study 28462869 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 120
Study 27507989 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% curcumin oral paste three times a day for four weeks
Number of subjects: 50
Study 27507989 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone three times a day for four weeks
Number of subjects: 50
Study 23322191 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methadone 2.5 mg with 40 mg lidocaine
Number of subjects: 72
Study 23322191 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methadone 5 mg with 40 mg lidocaine
Number of subjects: 72
Study 23322191 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methadone 7.5 mg with 40 mg lidocaine and 10 mg dexamethasone
Number of subjects: 72
Study 21844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic acyclovir therapy
Number of subjects: 615
Study 21844743 — intervention group
Group type: COMPARATOR
Intervention: Previous care seekers
Number of subjects: 615
Study 21844743 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in health care seeking
Number of subjects: 615
Study 18274504 — intervention group
Group type: EXPERIMENTAL
Intervention: Component Model of Reading (CMR) based reading instruction program over 7 years
Number of subjects: 0
Study 18274504 — intervention group
Group type: COMPARATOR
Intervention: Discrepancy model of learning disabilities
Number of subjects: 0
Study 16281062 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 351
Study 16281062 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg
Number of subjects: 351
Study 14690098 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 200
Study 14690098 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 15 mg
Number of subjects: 200
Study 10719650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytic therapy
Number of subjects: 0
Study 10719650 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis
Number of subjects: 0
Study 8605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (0.6 microgram/kg/hour for five days)
Number of subjects: 21
Study 8605558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil and Placebo (both groups)
Number of subjects: 21
Study 1419943 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-gauge nylon catheter
Number of subjects: 41
Study 1419943 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-gauge polyurethane catheter
Number of subjects: 41
Study 1419943 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-gauge polyimide catheter
Number of subjects: 41
Study 1419943 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-gauge polyurethane catheter
Number of subjects: 41
Study 1419943 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of all catheters
Number of subjects: 41
Study 4087290 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A winners
Number of subjects: 24
Study 4087290 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A losers
Number of subjects: 24
Study 4087290 — intervention group
Group type: COMPARATOR
Intervention: Type B winners and losers
Number of subjects: 24
Study 30853042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep health program (4 weekly group sessions)
Number of subjects: 63
Study 30853042 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 63
Study 29740768 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 t ha-1 CPM
Number of subjects: 0
Study 29740768 — intervention group
Group type: COMPARATOR
Intervention: Recommended dose of NPK (control)
Number of subjects: 0
Study 29740768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low irrigation regimes (I1 and I2)
Number of subjects: 0
Study 26250435 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IV)
Number of subjects: 351
Study 26250435 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (iron sulphate, 200 mg daily for 8 weeks)
Number of subjects: 351
Study 24941286 — intervention group
Group type: EXPERIMENTAL
Intervention: Out of School Nutrition and Physical Activity (OSNAP) intervention
Number of subjects: 20
Study 22990269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerobic training (40 min/d; n = 73)
Number of subjects: 222
Study 22990269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aerobic training (20 min/d; n = 71)
Number of subjects: 222
Study 22990269 — intervention group
Group type: COMPARATOR
Intervention: Control (usual physical activity; n = 78)
Number of subjects: 222
Study 19295388 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia with nitrous oxide
Number of subjects: 30
Study 19295388 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with nitrous oxide
Number of subjects: 30
Study 19295388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with nitrous oxide
Number of subjects: 30
Study 19295388 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia with air/oxygen
Number of subjects: 30
Study 19295388 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia with air/oxygen
Number of subjects: 30
Study 19295388 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with air/oxygen
Number of subjects: 30
Study 17439905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine-SR (10 to 40 mg twice daily, increasing in 5 mg increments weekly)
Number of subjects: 36
Study 17439905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15055251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of trandolapril
Number of subjects: 37
Study 15055251 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of trandolapril
Number of subjects: 37
Study 12453029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 3
Study 12453029 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3
Study 12453029 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 3
Study 12453029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9695314 — intervention group
Group type: EXPERIMENTAL
Intervention: ipriflavone 600 mg/day (OSTEN)
Number of subjects: 0
Study 9695314 — intervention group
Group type: EXPERIMENTAL
Intervention: elcatonin 20 IU/week (CT)
Number of subjects: 0
Study 9695314 — intervention group
Group type: EXPERIMENTAL
Intervention: daily oral administration of 2 g calcium lactate and 0.5 microgram alphacalcidol (Ca.D)
Number of subjects: 0
Study 9695314 — intervention group
Group type: EXPERIMENTAL
Intervention: repeated 14‐week cycle of daily oral administration of 2 micrograms alphacalcidol for 2 weeks, 600 mg of ipriflavone for 4 weeks, and 2 g calcium lactate together with 0.5 microgram alphacalcidol for 8 weeks (ADFR)
Number of subjects: 0
Study 9745809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin
Number of subjects: 61
Study 9745809 — intervention group
Group type: COMPARATOR
Intervention: 0.1% diclofenac
Number of subjects: 61
Study 1938312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 20 degrees C
Number of subjects: 54
Study 1938312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 25-26 degrees C
Number of subjects: 54
Study 1938312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 30 degrees C
Number of subjects: 54
Study 1938312 — intervention group
Group type: COMPARATOR
Intervention: Control for end tidal carbon dioxide measurements
Number of subjects: 54
Study 7197963 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 1 (standard formulation)
Number of subjects: 4
Study 7197963 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 2 (test formulation)
Number of subjects: 4
Study 31958547 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrapposto pose
Number of subjects: 0
Study 31958547 — intervention group
Group type: COMPARATOR
Intervention: Neutral standing pose
Number of subjects: 0
Study 30653262 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening (cut-off of 4.0 ng/ml), 2-3 screening rounds offered
Number of subjects: 81849
Study 30653262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-screen analysis
Number of subjects: 81849
Study 30653262 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no PSA screening)
Number of subjects: 81849
Study 28143496 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and paracetamol
Number of subjects: 0
Study 28143496 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and diclofenac
Number of subjects: 0
Study 28143496 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and placebo
Number of subjects: 0
Study 28143496 — intervention group
Group type: COMPARATOR
Intervention: Advice only (usual care)
Number of subjects: 0
Study 23295789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus rituximab (arm B)
Number of subjects: 227
Study 23295789 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (arm A)
Number of subjects: 227
Study 20971822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (40 mg/m(2)) and standard vincristine (2 mg) on day 1, followed by dexamethasone and a second cycle at day 28, reinforced by cyclophosphamide
Number of subjects: 60
Study 20971822 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion doxorubicin (12 mg/m(2)/day) and continuous-infusion vincristine (0.4 mg/day) on days 1-4
Number of subjects: 60
Study 19827483 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern dressings
Number of subjects: 0
Study 17082518 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow chart regarding the management of blood and body fluid exposures (Group B)
Number of subjects: 1120
Study 17082518 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail alert containing the flow chart (Group C)
Number of subjects: 1120
Study 17082518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral presentation of information in the flow chart (Group D)
Number of subjects: 1120
Study 17082518 — intervention group
Group type: COMPARATOR
Intervention: Face to face training (Group A - control)
Number of subjects: 1120
Study 15645954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 21
Study 15645954 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 21
Study 11358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily treatment of dithranol
Number of subjects: 16
Study 11358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly treatment of dithranol
Number of subjects: 16
Study 9298911 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin, tobramycin, and clindamycin
Number of subjects: 200
Study 9298911 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin, tobramycin, and ornidazole
Number of subjects: 200
Study 9298911 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin alone
Number of subjects: 200
Study 9298911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and ornidazole
Number of subjects: 200
Study 8362531 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (8 IU) plus HPN (1.0-1.5 g protein/kg/day and 900 kcal/day)
Number of subjects: 180
Study 8362531 — intervention group
Group type: COMPARATOR
Intervention: HPN only (control group)
Number of subjects: 180
Study 3017596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1 mg)
Number of subjects: 38
Study 3017596 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (20 mg)
Number of subjects: 38
Study 30184091 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of Ï‰‐6 PUFAs
Number of subjects: 0
Study 30184091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ï‰‐6 PUFAs
Number of subjects: 0
Study 27894461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 139
Study 27894461 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 139
Study 24104875 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg b.i.d. for 7 days)
Number of subjects: 110
Study 24104875 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 110
Study 23184077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with sodium bicarbonate
Number of subjects: 301
Study 23184077 — intervention group
Group type: COMPARATOR
Intervention: Hydration with 0.9% saline
Number of subjects: 301
Study 20352618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet with high intake of virgin olive oil (MD+VOO)
Number of subjects: 737
Study 20352618 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 737
Study 18999171 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment results distributed via email to collaborating institutions, with blinded recipients not notified of the subject's treatment selection.
Number of subjects: 0
Study 16043737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose parenteral insulin (human ultralente insulin at 0.25 units x kg(‐1) x day(‐1))
Number of subjects: 100
Study 11973483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus patients (n=27)
Number of subjects: 45
Study 11973483 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tinnitus patients (n=18)
Number of subjects: 45
Study 11973483 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=26)
Number of subjects: 45
Study 10209851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision (UC)
Number of subjects: 20
Study 10209851 — intervention group
Group type: COMPARATOR
Intervention: Clips/EndoGIA
Number of subjects: 20
Study 7726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training program (6-week protocol involving positive reinforcement, modeling, rehearsal, feedback, and time out)
Number of subjects: 32
Study 7726819 — intervention group
Group type: COMPARATOR
Intervention: Regular classroom activities (Control group)
Number of subjects: 32
Study 7726819 — intervention group
Group type: EXPERIMENTAL
Intervention: Social validity assessment via teachers' ratings of videotapes of pretest and posttest assessments
Number of subjects: 32
Study 1684872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.12 mg/kg)
Number of subjects: 0
Study 1684872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.24 mg/kg)
Number of subjects: 0
Study 1684872 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 6760660 — intervention group
Group type: EXPERIMENTAL
Intervention: Piloplex 3.4% b.i.d.
Number of subjects: 0
Study 6760660 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 2.0% q.i.d.
Number of subjects: 0
Study 31256846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 60
Study 31256846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 60
Study 31256846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 28102437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard endurance and strength training (SET)
Number of subjects: 19
Study 28102437 — intervention group
Group type: COMPARATOR
Intervention: Medical Qigong (QG)
Number of subjects: 19
Study 27681404 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit pulpectomy with zinc oxide eugenol (ZOE)
Number of subjects: 64
Study 27681404 — intervention group
Group type: COMPARATOR
Intervention: Two-visit pulpectomy with intracanal calcium hydroxide followed by obturation with ZOE
Number of subjects: 64
Study 25623462 — intervention group
Group type: EXPERIMENTAL
Intervention: Microecologic treatment combined enteral nutrition
Number of subjects: 60
Study 25623462 — intervention group
Group type: COMPARATOR
Intervention: Probiotics only
Number of subjects: 60
Study 25623462 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nutrition
Number of subjects: 60
Study 22827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nuts (35 g/d)
Number of subjects: 75
Study 22827780 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured soy protein (TSP) (35 g/d)
Number of subjects: 75
Study 22827780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 19208678 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (BEV/PPV group)
Number of subjects: 20
Study 19208678 — intervention group
Group type: COMPARATOR
Intervention: PPV only (PPV group)
Number of subjects: 20
Study 17205251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% in 50 ml of saline 0.9% (Group B)
Number of subjects: 46
Study 17205251 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% in 40 ml of saline 0.9% (Group C)
Number of subjects: 46
Study 17205251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%) (Group A)
Number of subjects: 46
Study 15140341 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 581
Study 15140341 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7 days
Number of subjects: 581
Study 15140341 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg once daily for 10 days
Number of subjects: 581
Study 11383931 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 21
Study 11383931 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 21
Study 11383931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9702472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8
Study 9702472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ANP (2.5 pmol kg‐1 min‐1)
Number of subjects: 8
Study 9702472 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ANP (5.0 pmol kg‐1 min‐1)
Number of subjects: 8
Study 7980309 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use for 6 months
Number of subjects: 222
Study 7980309 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ablative therapy
Number of subjects: 222
Study 7980309 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use after ablative therapy
Number of subjects: 222
Study 7980309 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control Group 1)
Number of subjects: 222
Study 2967742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (15 mg/day, 5 mg t.i.d.)
Number of subjects: 19
Study 2967742 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day, 80 mg t.i.d.)
Number of subjects: 19
Study 31709984 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified medical therapy guided by invasive coronary function testing
Number of subjects: 151
Study 31709984 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 151
Study 29911878 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Competence Intervention for Adolescents (SCI-A)
Number of subjects: 274
Study 29911878 — intervention group
Group type: COMPARATOR
Intervention: business-as-usual (BAU) practices
Number of subjects: 274
Study 28590767 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodanza
Number of subjects: 121
Study 25974723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement containing whey (LNS/w)
Number of subjects: 282
Study 25974723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement containing soy (LNS/s)
Number of subjects: 282
Study 25974723 — intervention group
Group type: COMPARATOR
Intervention: No lipid-based nutrient supplement (Control)
Number of subjects: 282
Study 25974723 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 516 G>T polymorphism
Number of subjects: 282
Study 23758902 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min motor electrical stimulation (ES)
Number of subjects: 14
Study 23758902 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min motor electrical stimulation (ES)
Number of subjects: 14
Study 23758902 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min motor electrical stimulation (ES)
Number of subjects: 14
Study 23758902 — intervention group
Group type: COMPARATOR
Intervention: Control for peripheral effects (M-waves)
Number of subjects: 14
Study 20807859 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteus muscle activation during squats
Number of subjects: 17
Study 20807859 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 17
Study 20807859 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat exercise
Number of subjects: 17
Study 20807859 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteus muscle-tendon unit exercise
Number of subjects: 17
Study 18445174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 147
Study 16564934 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (Kremezin) 0.9 g, 2.1 g, or 3.0 g, administered 3 times daily for 12 weeks
Number of subjects: 0
Study 16564934 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered 3 times daily for 12 weeks
Number of subjects: 0